EverGlade Insights

DTRA Funding Alert: Amendment to DTRA Chemical / Biological Technologies Broad Agency Announcement Includes Additional Funding Opportunities to Develop Bioinformatics Capabilities, Ocular Sampling Technologies, and MCMs for Chemical Warfare Agents On March 21, 2023, the Defense Threat Reduction Agency (DTRA) released an amendment to the current Broad Agency Announcement (BAA) seeking proposals that address the […]

New Funding Opportunities Available Through the New Advanced Research Projects Agency for Health (ARPA-H) BAA ARPA-H, or the Advanced Research Projects Agency for Health, is an agency within the National Institutes of Health (NIH) that aims to accelerate the development of breakthrough technologies and treatments for major diseases. ARPA-H has been likened to the Defense

Amendment to BAA Outlines New DTRA Funding Opportunities to Develop Novel Technologies and Medical Countermeasures Against Weapons of Mass Destruction (WMD) and Emerging Threats The Defense Threat Reduction Agency (DTRA) recently published an amendment to their Broad Agency Announcement (‘BAA”) No. HDTRA1-22-S-0003, which provides additional funding opportunities to identify and counter Weapons of Mass Destruction

New Strategy Leads to New Funding Opportunities for the Development of Medical Countermeasures In the wake of the Coronavirus Disease 2019 (COVID-19) pandemic and a rapidly expanding landscape of biological and chemical threats, the Department of Defense (DoD) is initiating a new approach to developing Medical Countermeasures (MCM) for Joint Force protection. The Office of

EverGlade Consulting (“EverGlade”), a national consulting firm, has helped a leading biotechnology company land an award from the Biomedical Advanced Research and Development Authority (BARDA) with a potential $1 billion in federal funding. This multi-year contract will allow the Company to advance the development of a full portfolio of innovative solutions to address influenza and

President Biden recently launched the administration’s new National Biodefense Strategy and Implementation Plan. The strategy reflects changing dynamics in Washington, especially given the lack of additional funding for COVID.  National BiodefenseStrategy and Implementation Summarized The plan calls for $88B in additional funding over 5 years and is focused on the following goals: Detect pandemics and

As we enter a new era of diversity, equity, and inclusion in today’s evolving business ecosystem, Eric Jia-Sobota has been appointed to the Victory Fund Board of Directors. This appointment furthers both Eric and EverGlade Consulting’s commitment to diversity as a Certified LGBT Business Enterprise® with the National LGBT Chamber of Commerce. The Board of

EverGlade Consulting (“EverGlade”), a national consulting firm, has successfully partnered with a global leader in mRNA materials used for research, diagnostics, and therapeutics, to successfully manage $39 million in federal funding. The Industrial Base Expansion (IBx) project will expand the domestic production capacity for materials that are critical to the development and manufacture of mRNA

As of August 10, the Center for Disease Control (CDC) reported that over 10,000 cases of monkeypox have been identified in the United States (US). The Biden administration officially declared monkeypox a Public Health Emergency (PHE) in the US on August 4th, following several states that declared their own state of emergency (New York, California,

With the government fiscal year ending in a few short weeks and Covid continuing to impact the country, new government funding opportunities are plentiful for organizations supporting both the pandemic response and other areas of interest in the new Senate appropriations bill which will head for a vote by September 30, 2022. One of the

EverGlade Consulting (“EverGlade”), a Washington, D.C. based consulting firm, has successfully aided Detect, Inc. (“Detect”) in securing a contract with BARDA for the advanced development of a next-generation diagnostic device which is an over-the-counter home test that identifies and distinguishes between SARS-CoV-2 and influenza A and B nucleic acid using a single nasal swab.